Back3D Medicines Overview

3D Medicines EBIT

3D Medicines's EBIT is $-390M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$77.86M
↑ 22.58% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$388.73M
↑ 52.02% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

3D Medicines (1244.HK) FAQ

The latest EBIT for 1244.HK is $-390M as of June 2026. That compares with $-810M in the prior-year period — up 52.0% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside 3D Medicines's historical trend and sector peers before judging valuation or financial health.

Over the past year, 1244.HK's EBIT moved from $-810M to $-390M — a 52.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 3D Medicines's operating scale or balance-sheet position.

Against Healthcare companies, 1244.HK currently prints $-390M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at 3D Medicines's growth, margins, and balance sheet.

A EBIT figure of $-390M for 1244.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting 1244.HK's EBIT ($-390M), review year-over-year change from $-810M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.